Filing Details

Accession Number:
0001209191-16-111235
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-03-31 16:59:07
Reporting Period:
2016-03-29
Filing Date:
2016-03-31
Accepted Time:
2016-03-31 16:59:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1631650 Aimmune Therapeutics Inc. AIMT () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1253886 G Patrick Enright 800 El Camino Real, Suite 220
Menlo Park CA 94025
No No Yes No
1431159 Juliet Bakker Tammenoms 800 El Camino Real, Suite 220
Menlo Park CA 94025
No No Yes No
1527510 Longitude Venture Partners Ii, L.p. 800 El Camino Real, Suite 220
Menlo Park CA 94025
No No Yes No
1647491 Longitude Capital Partners Ii, Llc 800 El Camino Real, Suite 220
Menlo Park CA 94025
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.0001 Par Value Acquisiton 2016-03-29 33,064 $13.50 7,467,694 No 4 P Indirect By Longitude Venture Partners II, L.P.
Common Stock, $0.0001 Par Value Acquisiton 2016-03-29 45,440 $14.15 7,513,134 No 4 P Indirect By Longitude Venture Partners II, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Longitude Venture Partners II, L.P.
No 4 P Indirect By Longitude Venture Partners II, L.P.
Footnotes
  1. Reflects purchases of ordinary shares executed in multiple transactions at prices ranging from $12.90 to $13.89. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.
  2. This report is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. Longitude Capital II as general partner of Longitude Venture II maybe deemed to have sole voting, investment and dispositive power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are each managing members of Longitude Capital II and in their capacity as such, may be deemed to exercise shared voting and investment power over the shares held by Reporting Persons. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.
  3. Reflects purchases of ordinary shares executed in multiple transactions at prices ranging from $13.90 to $14.29. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.